Advanced Biotherapy Inc., of Woodland Hills, Calif., added Richard Kiphart to its board.

Advanced Viral Research Corp., of Yonkers, N.Y., named Roy Walzer to its board.

Allos Therapeutics Inc., of Westminster, Colo., elected Michael Casey to its board.

Amphora Discovery Corp., of Research Triangle Park, N.C., added Cesar Collado as vice president of business development and commercialization and Holly Marcum as executive director of business development and commercialization.

Amylin Pharmaceuticals Inc., of San Diego, added Tony Chin as vice president of quality assurance.

Argenta Discovery, of Harlow, UK, named Neil Harris and Hazel Hunt directors of chemistry.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Elizabeth Wyatt, Michael Kishbauch, Frederick Schiff and Burton Sobel to its board.

Beyond Genomics Inc., of Waltham, Mass., appointed Jim Hauske chief scientific officer.

Biotechnology Industry Organization, of Washington, appointed Andrew Baum to its board.

Celator Technologies Inc., of Vancouver, British Columbia, appointed Alan Sartorelli, Dario Altieri, Joseph Bertino, Stephen Carter, Edward Chu, Emil Frei, William Hait and John Lazo to its scientific advisory board.

Corus Pharma Inc., of Seattle, named William Baker vice president of research.

CytoGenix Inc., of Houston, elected Scott Parazynski and Frank Vazquez to its board.

Deltagen Inc., of Redwood City, Calif., appointed Edward Penhoet to its board.

Devgen NV, of Ghent, Belgium, appointed Vincenzo Facchini head of research and development.

DOR BioPharma Inc., of Lake Forest, Ill., appointed Arthur Kornbluth and Peter Salomon to its board.

EngeneOS Inc., of Waltham, Mass., appointed Stephen Benkovic to its scientific advisory board.

Exelixis Inc., of South San Francisco, added Steven Lacy as senior director, preclinical development.

GeneFormatics Inc., of San Diego, added Peter Domaille as director, structural biology.

Genencor International Inc., of Palo Alto, Calif., added Theresa Lee and Gregory Nelson to its board.

Genomics Collaborative Inc., of Cambridge, Mass., promoted Kevin Krenitsky to senior vice president and medical director and named Roberto Rodriguez senior director of business development, genomics.

Gen-Probe Inc., of San Diego, will add James Godsey as executive vice president, development, as of July 8.

GenVec Inc., of Gaithersburg, Md., elected William Kelley to its board.

GlycoDesign Inc., of Toronto, appointed Brian Fielding vice president, finance and chief financial officer.

Guilford Pharmaceuticals Inc., of Baltimore, appointed Jean-Marie Vallet vice president of business development.

Helix BioMedix Inc., of Bothell, Wash., added George Murray to its board and named Parker Sroufe executive vice president and Kerry Palmer chief financial officer.

Hyseq Pharmaceuticals Inc., of Sunnyvale, Calif., appointed Mary Pendergast and Richard Brewer to its board.

Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed David Shlaes executive vice president, research and development.

Trimeris Inc., of Durham, N.C., appointed George Koszalka senior vice president of corporate strategy.

XTL Biopharmaceuticals Ltd., of Cambridge, Mass., appointed Glenn Kazo to its board.

Zarix Inc., of Berwyn, Pa., named Fred Powell chief financial officer.